Opzelura União Europeia - dinamarquês - EMA (European Medicines Agency)

opzelura

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - andre dermatologiske præparater - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Inlyta União Europeia - dinamarquês - EMA (European Medicines Agency)

inlyta

pfizer europe ma eeig  - axitinib - carcinom, nyrecelle - protein kinase hæmmere - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Seretide 50+250 mikrog./dosis inhalationspulver, afdelt Dinamarca - dinamarquês - Lægemiddelstyrelsen (Danish Medicines Agency)

seretide 50+250 mikrog./dosis inhalationspulver, afdelt

glaxosmithkline pharma a/s - fluticasonpropionat, salmeterolxinafoat - inhalationspulver, afdelt - 50+250 mikrog./dosis

Leqvio União Europeia - dinamarquês - EMA (European Medicines Agency)

leqvio

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipid modificerende midler - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Saphnelo União Europeia - dinamarquês - EMA (European Medicines Agency)

saphnelo

astrazeneca ab - anifrolumab - lupus erythematosus, systemisk - immunosuppressiva - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.